Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.

EClinicalMedicine · 2025 · PMC11925540 · PMID 40115173

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significancep = 0.051so close (0.05 < p ≤ 0.1)

2/6 patients, Fisher test (double one sided), p = 0.11) while the difference in PFS did not reach statistical significance (33 vs. 13 months, Log rank test, p = 0.051) and OS was statistically superior (NR vs. 13 months, Log rank test, p = 0.0050) (data not shown).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.